Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palopegteriparatide (Primary)
  • Indications Hypoparathyroidism
  • Focus Registrational; Therapeutic Use
  • Acronyms PaTH Forward
  • Sponsors Ascendis Pharma

    • Most Recent Events

    • 30 Sep 2024 According to a Ascendis Pharma media release, data from this trial presented at ASBMR 2024
    • 30 Sep 2024 Results published in the Ascendis Pharma Media Release
    • 13 Aug 2024 According to a Ascendis Pharma media release, the company announced that the U.S. Food & Drug Administration (FDA) has approved YORVIPATH for the treatment of hypoparathyroidism in adults. The FDA based its approval of YORVIPATH on their review of the clinical package for TransCon PTH (palopegteriparatide) submitted with the Companys New Drug Application, including data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top